Barinthus Biotherapeutics (BRNS) EBT Margin (2020 - 2024)

Barinthus Biotherapeutics' (BRNS) quarterly EBT Margin came in at 54.33% in Q3 2024, up 99.27% on a QoQ basis from 7473.05% in Q2 2023.

Barinthus Biotherapeutics (BRNS) EBT Margin (2020 - 2024) Analysis & Trends

Barinthus Biotherapeutics (BRNS) has 5 years of EBT Margin data on file, last reported at 54.33% in Q3 2024.

Quarterly EBT Margin changed N/A year-over-year to 54.33% in Q3 2024, while the trailing twelve-month figure through Dec 2025 was 445.14% (down 3611.0% YoY) and the FY2024 annual result came in at 409.03%, up 913237.0% from the prior year.
EBT Margin grew to 54.33% in Q3 2024, from 7473.05% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 1666800.0% in Q4 2021 to a low of 48128.57% in Q2 2021.
A 5-year average of 104035.54% and a median of 670.07% in 2020 frame the typical range for EBT Margin.
Annual changes were most pronounced in 2021 — EBT Margin surged 167043418 bps — and 2022, when it tumbled 166715902 bps.
Tracing BRNS's EBT Margin over 5 years: stood at 3634.18% in 2020, then jumped by 45965 bps to 1666800.0% in 2021, then sank by 100 bps to 359.02% in 2022, then tumbled by 1982 bps to 7473.05% in 2023, then soared by 99 bps to 54.33% in 2024.
The last three EBT Margin figures came in at 54.33% (Q3 2024), 7473.05% (Q2 2023), and 4004.06% (Q1 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	35.61%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	35.71%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	13.77%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-2.67%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-25.06%
10	Barinthus Biotherapeutics	25.01 Mn	25.01 Mn	-	-

Download Data